Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAMSAL: Dolutegravir vs Efavirenz 400 mg for HIV-1 in Cameroon
NCT02777229Phase 3Completed
- Sponsor
- ANRS
- Start
- Jul 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ANRS. Started Jul 2016; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02777229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777229.